PR: Stardots launches beta version of its Psilmi™ platform for autism and ADHD diagnosis and establishes new clinical partnerships

Uppsala, Sweden – September 12, 2025 – Stardots AB – a leading developer of software medical devices to simplify and improve the diagnosis and treatment of neurological and psychiatric conditions – today announces the beta launch of its Psilmi platform and the expansion of its clinical partnership network. The new collaborations with prominent universities will advance the use of digital biomarkers for autism and ADHD to support clinical decision-making.

Stardots is developing medical device software (SaMD) to optimize diagnostics and treatment of neurological and psychiatric conditions, using research-backed advanced mathematical modeling of sensor data. Psilmi aims to offer a more timely and accurate diagnosis, and individualized care, for psychiatric conditions such as autism, ADHD, anxiety, and depression.

Today, Stardots launches the beta version of the patent-pending Psilmi platform, inviting partnering clinics to use Stardots’ software for research and data collection purposes. Building on its existing collaboration with Uppsala University, Stardots is expanding its partner network to include clinics and Universities in EU, Africa and Asia.

“We are proud to launch Psilmi today – a major step forward for us as a company and for the continued development of using objective biomarkers as diagnostic support in hard-to-catch diagnosis. At the same time, welcoming new collaboration partners validates our technology and will expand the collection of patient data and enhance the population diversity in the data, creating a stronger foundation for continued development. Together, we will continue to advance the Psilmi platform with the ambition to make it a powerful diagnostic tool in clinical use and a future medical device. We believe that the platform has the potential to become a game changer in psychiatric diagnostics,” says Daniel Petrini, CEO of Stardots.

Recently, a pilot study conducted at Uppsala University, evaluating the Psilmi algorithms, has shown promising results. A total of 178 adults participated in the study including neurotypical controls, and people with prior diagnosis of autism, ADHD, anxiety or depression. All participants were highly functioning, which makes prediction challenging. Despite this, the results showed distinct differences in pupillary regulation and revealed clusters of biomarkers correlating with different diagnoses, making it plausible to separate the diagnoses with a high mean accuracy ~90%. The results indicate that eye-tracking measurements provide a good basis for objective biomarkers.

About Psilmi™

Psilmi is a platform aimed at more accurate and early diagnosis of autism, ADHD, depression and anxiety, especially in children. Backed by over 10 years of research at Uppsala University, scientists have identified biomarkers linked to the underlying biology of these conditions. These biomarkers can increase the chances of early and precise diagnosis in young children or hard-to-catch cases. This would reduce lead times in healthcare and additionally facilitate targeted and individualized interventions. Stardots is now implementing these biomarkers in an application to make the testing easy to use in clinical practice. The development and clinical trials are taking place in collaboration with Uppsala University. FDA clearance through a 510(k) submission is anticipated in late 2026.

For further information, please contact:
Daniel Petrini, CEO
Tel: +46 70-782 70 01
E-mail: daniel.petrini@stardots.se

About Stardots AB
Stardots AB develops software-based diagnostic tools and clinical decision support (Software as Medical Device) for neurological and psychiatric conditions such as Parkinson’s, autism, ADHD, dementia and Alzheimer’s. The company’s product platforms ANLIVA®, Psilmi™ and QUEST use advanced mathematical modeling of sensor data from smartphones, eye cameras and other sensors to enable faster and more reliable diagnosis and optimized treatment. Stardots’ first wave of products, ANLIVA® Hand Movement, ANLIVA® Eye Movement, and ANLIVA® Deep Brain Stimulation for Parkinson’s disease, is currently being evaluated in a clinical trial in collaboration with Dartmouth Hitchcock Medical Center in the U.S. Stardots, headquartered in Uppsala, Sweden, has the U.S. as its primary target market.
For further information, visit www.stardots.se.